

DAFTAR PUSTAKA

1. Deteksi dini kanker payudara. Republika online; 2006 April 2. Diakses tanggal 14 Juli 2009. Dari:http://www.republika.co.id/cetak_berita.asp.
2. Smigal C, Siegel R. Breast cancer facts and figure 2005-2006. American cancer society; 2005:1-3. Diakses tanggal 11 November 2009. Dari:<http://www5.cancer.org/downloads/STT/CAFF2005BrFacspdf2005.pdf>.
3. Cancer statistic review 1975-2005. National Cancer Institute. 2008. Diakses tanggal 14 Juli 2009. Dari:www.seer.cancer.gov/csr/1975-2005.
4. Jemal A, Siegel R, Ward A, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. *Ca Cancer J Clin* 2009; 59:225-49. American Cancer Society.
5. Breast cancer statistics. Diakses tanggal 15 September 2010. Dari:http://www.breastcancer.org/symptoms/understand_bc/statistics.jsp.
6. Kardinah. Kanker payudara : bagaimana hindari berbagai ancaman. DEPKES-RI ; 2007. Diakses tanggal 11 Agustus 2009. Dari:<http://www.depkes.go.id/kanker.htm>.
7. Aziz MF. Masalah pada kanker serviks. *Cermin Dunia Kedokteran*. 2001;133:15-8.
8. Sugito H. Kanker di Indonesia tahun 1994 data histopatologik. Badan Registrasi Kanker Ikatan Ahli Patologi Indonesia. Dirjen YanMed Dep. Kes RI ; 1994:3-6.
9. Profil kesehatan Provinsi Jawa Tengah tahun 2005. Pencapaian Program kesehatan menuju Jawa Tengah sehat. Dinas Kesehatan Pemerintah Provinsi Jawa Tengah; 2005. Diakses tanggal 20 Oktober 2009. Dari:<http://www.dinkesjateng.org/profil2005/bab4.htm>.
10. Shirley IM. Epidemiologi kanker payudara dan pengendaliannya. *Medika* 2000;5:326- 9.
11. Survei kesehatan rumah tangga (SKRT). Jakarta (INA): Badan Penelitian dan Pengembangan Kesehatan, Departemen Kesehatan RI dan Biro Pusat Statistik; 1992. p. 44.
12. Baretta G. *Cancer treatment medical guide*. 10th ed. Milan: Farmitalia Carlo Erba-Erbamont; 1991. p. 174-6.
13. Dickson R B, Lippman M E. Cancer of the breast. In: Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg, editors. *Cancer: principles & practice of oncology*. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005. p. 1400-62.
14. Sobin LH, Wittekind CH, editors. *Classification of malignant tumours TNM*. International union against cancer UICC. 6th ed. A John Wiley & Sons Inc..

2002. p. 131-41.

15. Harmey JH, editor. VEGF and cancer. Landes Bioscience. Kluwer Academic/Plenum Publisher. 2004.
16. Hanahan D, Weinberg RA. The hallmark of cancer. *Cell*. 2000;5:57-70.
17. Sledge GW. VEGF-targeting therapy for breast cancer. *J Mammary Gland Biol Neoplasia*. 2005;10:319-23.
18. Ferrara N. VEGF and its receptors. In Harmey JH, editor. VEGF and cancer. Texas: Kluwer academic/Plenum Publishers; 2004. p. 1-5.
19. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar K, Sung B. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. *Exp Biol Med*. 2009; 234:825-49.
20. Yance D. Cancer and inflammation: the emerging role of botanical compounds in targeting proinflammatory pathways, with particular attention to the NF- κ B signaling pathway. Diakses tanggal 6 April 2010. Dari: [http://www.centrehealing.com/files/NF- \$\kappa\$ Bpaper.pdf](http://www.centrehealing.com/files/NF-κBpaper.pdf).
21. Agoes A. Mahkota dewa (*Phaleria macrocarpa* [scheff] boerl.). In: Tanaman obat Indonesia buku 2. Salemba Medika. 2010. p. 71-3.
22. Gupta SC, Kim JH, Prasad S, Aggarwal B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. *Cancer Metast Rev*. 2010;29:405-34.
23. Matsubara K, Mizushima Y. Green tea catechin as angiogenesis inhibitor. In: Mc Kinley H, Jamieson M, editors. Food and beverage consumption and health series. New York: Nova Science Publisher, Inc.; 2009. p. 198-9.
24. Rosengren RJ. Utility of eppigallocatechin gallate in the treatment and prevention of breast cancer: molecular mechanisms for tumor suppression. In: Mckinley H, Jamieson M, editors. Food and beverage consumption and health series. New York: Nova Science Publisher, Inc.; 2009. p. 308-314.
25. Wenzel U, Daniel H. Polyphenols and gene expression. In: Daayf F, Lattanzio V, editors. Recent advances in polyphenols research. West Sussex: Blackwell Publishing Ltd; 2008. p. 363-68.
26. Lisdawati V. *Phaleria macrocarpa*, toksisitas, efek anti oksidan, dan efek anti-kanker berdasarkan uji penapisan farmakologi. Jakarta (INA): PT *Phaleria macrocarpa*; 2002. Diakses tanggal 16 Juli 2007.:
Dari: <http://www.indonetwork.phalerindofarma/34716.htm>.
27. Harmanto N. Mahkota dewa obat pusaka para dewa. AgroMedia Pustaka. Jakarta; 2005.

28. Lin YG, Kunnumakkara AB, Nair A, Merrit WM, Han LY, Armaiz-Pena GN et al. Curcumin inhibit tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor- κ B pathway. *Clin Cancer Res*. 2007;13(11).
29. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of I κ B α kinase and Akt activation. *Mol Pharmacol*. 2006;69:195-206.
30. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor- κ B-regulated gene products. *Cancer Res J*. 2007;67(8):3853–61.
31. Sung B, Pandey MK, Nakajima Y, Nishida H, Konishi T, Chaturvedi MM et al. Identification of a novel blocker of I κ B α kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor- κ B. *Mol Cancer Ther*. 2008;7(1):191–201.
32. Oak MH, Bedoui JE, Schini-Kerth VB. Antiangiogenic properties of natural polyphenols from red wine and green tea. *J Nutr Biochem*. 2005;16:1-8.
33. Marier JF, Chen K, Prince P, Scott G, del Castillo JR, Vachon P. Production of ex vivo lipopolysaccharide-induced tumor necrosis factor- α , interleukin-1 β , and interleukin-6 is suppressed bay trans-resveratrol in a concentration-dependent tumor. *Can J Vet Res*. 2005;69(2):151-4.
34. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. *Cancer Prev Res* 2009;2:409.
35. Li J, Zhang D, Stoner GD, Huang C. Differential effects of black raspberry and strawberry extracts on BaPDE-induced activation of transcription factors and their target genes. *Mol Carcinogen*. 2008;47(4):286-94.
36. Amit KT, Madhumita R, Bhattacharya RK. Natural products as inducers of apoptosis: Implication for cancer therapy and prevention. *Curr Sci*. 2001;80(11):1387-96.
37. Budijitno S, Issakh B, Handojo D, Pudjonarko D, Riwanto I. Pengaruh ekstrak mahkota dewa (*Phaleria macrocarpa*) terhadap skor ekspresi perforin CTL dan sel-NK serta indeks apoptosis pada adenokarsinoma mamma mencit C3H [Tesis]. *M Med Indones J* 2007;42(1):13-20.
38. Budijitno S, Issakh B, Handojo D, Pudjonarko D, Riwanto I. Pengaruh ekstrak mahkota dewa (*Phaleria macrocarpa*) terhadap skor ekspresi perforin CTL dan sel-NK serta perkembangan massa tumor adenokarsinoma mamma mencit C3H. *M Med Indones J*. 2007;42(3):37-40.
39. Widyasari A, Riastiti Y, Astuti I, Susilowati R, Harijadi. Efek biji mahkota dewa terhadap ekspresi caspase-3 aktif pada *cell line* ca colon widr. *Berkala*

Ilmu Kedokteran. 2006; 38(1):24-9.

40. Syukri Y, Saepudin. Aktivitas antikarsinogenesis ekstrak etanol daging buah mahkota dewa pada mencit yang diinduksi 7,12-dimetilbenz(a)antrasena. *J Ilmu Kefarmasian Indones*. 2008;6(2):63-7.
41. Tandrasasmita OM, Lee JS, Baek SH, Tjandrawinata RR. Induction of cellular apoptosis in human breast cancer by DLBS1425, a phaleria macrocarpa compound extract, via downregulation of p13-kinase/akt pathway. *Cancer Biol Ther*. 2010;10(8).
42. Sumastuti R, Sonlimar M. Efek sitotoksik ekstrak buah dan daun Phaleria macrocarpa terhadap sel hela. Yogyakarta: Farmakologi FK UGM; 2003. p. 1-12.
43. Sukemti, Soegihardjo CJ. Uji toksisitas akut buah mentah mahkota dewa (Phaleria macrocarpa Boerl.) terhadap larva Artemia salina Leach. beserta profil kromatografi fraksi paling aktif (skripsi). Yogyakarta: Prodi Farmasi UII; 2004.
44. What is breast cancer? American cancer society. 2009. Diakses tanggal 20 November 2009. Dari: <http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-what-is-breast-cancer?sitearea=>
45. Lynch HT, Marcus JN, Lynch JF, Snyder CL, Rubinstein WS. Breast cancer genetics: heterogeneity, molecular genetics, syndrome diagnosis, and genetic counseling. In Bland KL, Copeland EM. editors. The breast comprehensive management of benign and malignant disorders. 3rd ed. Missouri: Saunders; 2004. p. 375-92 .
46. Moll UM, Concina N. p53 in human cancer-somatic and inherited mutations and mutation-independent mechanism. In: Zambetti GP, editor. The p53 tumor suppressor pathway and cancer. New York: Springer Science Business Media Inc.; 2005. p. 115-27.
47. Steward W, Thomas A. The burden of cancer. In: Pelengaris S, Khan M, editors. The molecular biology of cancer. Oxford: Blackwell Publishing Ltd.; 2006. p. 42-6.
48. Pelengaris S, Khan M. Oncogenes. In: Pelengaris S, Khan M, editors. The molecular biology of cancer. Oxford: Blackwell Publishing Ltd.; 2006. p. 158-215.
49. Liu MC, Dicson RB, Lippman ME, Gelmann EP. Molecular oncology of breast cancer. In Bland KL, Copeland EM. editors. The breast comprehensive management of benign and malignant disorders. 3rd ed. Missouri: Saunders; 2004. p. 499-519.
50. Wakai K, Dillon DS, Ohno Y, Prihartono J, Budiningsih S, Ramli M, et al. Fat intake and breast cancer risk in an area where fat intake is low: a case-control study in Indonesia. *Int J Epidemiol*. 2000; 29:20-8.

51. Reed SI. Cell cycle. In Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg, editors. *Cancer: principles & practice of oncology*; 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005. p. 90-1.
52. Bufalo DD, Trisciuoglio D, Milella M. Cross talk between VEGF and bcl-2 in tumor progression and angiogenesis. In: Harmey JH, editor. *VEGF and cancer*. Texas: Kluwer academic/Plenum Publishers; 2004. p. 1-5.
53. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol*. 2006;71:1397-1421.
54. Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, et al. The canonical NF- κ B pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. *Cancer Res*. 2010 Dec 15;70(24):10464-73.
55. Roche. *Understanding VEGF and anti-angiogenesis* [pamphlet]. Hoffman-La Roche, Macclesfield Cheshire UK; 2004. p. 2-40.
56. Folkman MJ. Angiogenesis in breast cancer. In Bland KI, Copeland EM, editors. *The breast: comprehensive management of benign and malignant disorders*. 3rd ed. Philadelphia: Saunders; 2004. p. 563-86.
57. Donnini S, Ziche M, Morbidelli L. Molecular mechanisms of VEGF-induced angiogenesis. In: Harmey JH, editor. *VEGF and cancer*. Texas: Kluwer Academic/Plenum Publishers; 2004. p. 19-23.
58. Shima DT, Ruhrberg C. Angiogenesis. In: Pelengaris S, Khan M, editors. *The molecular biology of cancer*. Oxford: Blackwell Publishing Ltd.; 2006. p. 411-22.
59. Los M, Gibson SB, editors. *Apoptotic pathways as targets for novel therapies in cancer and other diseases*. Springer. 2005. p. 79-84.
60. Abbas A, Lichtman AH, Pober JS. *Cellular and molecular immunology*. 5th ed. Philadelphia: Elsevier-Saunders; 2005. p. 4-15,22-3,65-80,81-103,182-7,227-31,244-53,258-9,266,268-9,279-80,289-5.
61. Singletary SE. Investigational molecular prognostic factors for breast carcinoma. In: Bland KI, Copeland EM, editors. *The breast: comprehensive management of benign and malignant disorders*. 3rd ed. Philadelphia: Saunders; 2004. p. 462.
62. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell J. *Molecular cell biology*. 4th ed. New York: Scientific American Books; 2000:1247-70.
63. Karna P, Yang L. Apoptotic signaling pathway and resistance to apoptosis in breast cancer stem cells. In: Chen G, Lai PBS. Editors. *Apoptosis in carcinogenesis and chemotherapy: apoptosis in cancer*. New York: Springer; 2009. p. 1-24.

64. Kruyt FAE, Rodriguez JA, Giaccone G. Apoptosis pathways and new anticancer agents. In: Bronchud MH, editor. Principles of molecular oncology. 3rd ed. New Jersey: Humana Press Inc.; 2008. p. 257-60.
65. Soini Y, Paakko P, Lehto V. Histopathological evolution of apoptosis in cancer. *Am J Pathol.* 1998;153:1041-53.
66. Regner M, Mullbacher A. Granzymes in cytolytic lymphocytes – to kill a killer? *Immunol Cell Biol.* 2004;82:161-9.
67. Bird CH, Sun J, Ung K. Cationic sites on granzymes B contribute to cytotoxicity by promoting its uptake into target cells. *Mol Cell Biol.* 2005;25(17):7854-67.
68. Miller DM, Bates PJ, Nabell L. Molecular biology of breast cancer. In: Donegan WL, Spratt JS. editors. Cancer of the breast. St. Louis: Saunders; 2002. p. 181-9.
69. Roche. Bevacizumab, the first anti-VEGF monoclonal antibody for the effective first-line treatment of metastatic colorectal cancer. In: Product monograph [pamphlet]. Hoffman-La Roche, Macclesfield Cheshire UK; 2005. p. 4-12.
70. The Wikipedia free encyclopedia. Vascular endothelial growth factor. Adelaide: Wikimedia Foundation Inc; 2007. p. 12-21.
71. Shen BQ, David YL, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase c signaling pathway. *J Biol Chem.* 1999; 274: 33057-63.
72. Latzsch T, Hefler L. Vascular endothelial growth factor in breast cancer. In: Harmey JH, editor. VEGF and cancer. New York: Kluwer Academic/Plenum Publisher. 2004. p. 40-4.
73. Morbidelli L, Donnini S, Ziche M. Nitric oxide in tumor angiogenesis. In: Figg AD, Folkman J, editors. Angiogenesis: an integrative approach from science to medicine. New York: Springer Science+Business Media; 2008. p. 193-204.
74. Kawamura H, Li Xiujuan, Welsh M, Claesson LW. VEGF signal transduction in angiogenesis. In: Figg AD, Folkman J. editors. Angiogenesis: an integrative approach from science to medicine. New York: Springer Science+Business Media; 2008. p. 205-16.
75. Brahim-Horn MC, Laferrriere J, Mazure N, Pouyssegur J. Hypoxia and tumor angiogenesis. In: Marme D, Fusenig N. editors. Tumor angiogenesis = basic mechanism and cancer therapy. Heilderberg: Springer; 2008. p. 171-6.
76. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr. Rev. Endocrine Society.* 2004; 25(4):581-611.

77. Levy NS, Goldberg-Cohen I, Levy AP. Hypoxic regulation of VEGF. In Harmey JH, editor. VEGF and cancer. Texas: Kluwer Academic/Plenum Publishers; 2004. p. 12-17.
78. Pietras A, Johnsson AS, Pahlman S. The HIF-2 α -driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. In: Simon MC, editor. Diverse effects of hypoxia on tumor progression. Philadelphia: Springer; 2010. p. 5-7.
79. Bufalo DD, Trisciuglio D, Milella M. VEGF and bcl-2 in tumor progression and angiogenesis. In: Harmey JH. Editor. VEGF and cancer. New York: Kluwer Academic/Plenum Publisher. 2004. p. 26-39.
80. Ryd'en L, Linderholm B, Nielsen NH, Emdin S, Jönsson P, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. *Breast Cancer Res Treat.* 2003 Dec; 82(3):147-54.
81. Gustin A, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR et al, Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MPSK1 signaling pathway in endothelial cells. *Am J Physiol Cell Physiol.* 2004 March;286(3):547-55.
82. World Health Organization. Research guidelines for evaluating the safety and efficacy of herbal medicines. New York; 1993. p. 44.
83. Pambayun R, Gardjito M, Sudarmadji S, Kuswanto KR. Kandungan fenol dan sifat antibakteri dari berbagai ekstrak produk gambir (*uncaria gambir roxb*). *Indonesian J Pharm.* 2007;18(3),141-6.
84. Imono AD. Obat tradisional dan fitoterapi (uji toksikologi). Yogyakarta: Universitas Gajah Mada; 1986. p. 3-21.
85. Vision biosystems originTM mouse monoclonal antibody ORG-8871 [package insert].
86. Kato T, Kimura T, Ishii N, Fujii A, Yamamoto K, Kameoka S, et al. The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in Japanese patients with breast cancer. *Br Cancer Res Treat.* 1999;53:19-31.
87. Budiarto E. Biostatistika untuk kedokteran dan kesehatan masyarakat. Jakarta. EGC. 2002.
88. Dahlan MS. Statistik untuk kedokteran dan kesehatan. Jakarta. Salemba Medika. 2008. p. 26-58, 8s3-119, 158-62.
89. Mycek MJ, Harvey RA, Champe PC. Farmakologi ulasan bergambar. Jakarta: Widya Medika; 2001. p. 21.